Follow us on
SMS-oncology

Archive

2015

Direction is in our DNA

Direction is in our DNA

10 July 2015, Lindy Bosch, Business Developer

"Direction is so much more important than speed. Many are going nowhere fast". In my opinion, this quote recently displayed on social media describes exactly what we at SMS-oncology stand for. In the past few months we have been quite...Read more

ASCO 2015: Transforming Data into Learning

ASCO 2015: Transforming Data into Learning

1 June 2015, Raymond Hoffmans, Chief Business Development Officer

Currently one of the largest and most respected cancer conferences - the annual meeting of the American Society of Clinical Oncology (ASCO) - is ongoing. Over 30.000 oncology professionals (including our CEO Edwin Klumper) are attending...Read more

Scientific snapshots from the CIMT meeting

Scientific snapshots from the CIMT meeting

19 May 2015, Raymond Hoffmans, Chief Business Development Officer

Last week, SMS-oncology attended the annual Association for Cancer Immunotherapy (CIMT) meeting, which was held May 11-13 in Mainz, Germany. This European conference has been organized since 2002 and allows for both academic and industry...Read more

AACR 2015 - immunotherapy trials in the limelight

AACR 2015 - immunotherapy trials in the limelight

28 April 2015, Nadina Grosios, Director Consultancy

Immunotherapy and especially immune checkpoint inhibition continued to occupy the centre stage at this year's meeting of the American Association for Cancer Research (AACR) in Philadelphia. Among many cancer immunotherapy presentations,...Read more

'Inhibit the inhibitor' - it's all about PD-(L)1 inhibitors in cancer treatment

'Inhibit the inhibitor' - it's all about PD-(L)1 inhibitors in cancer treatment

30 March 2015, Lindy Bosch, Business Developer

PD-1 and PD-L1 inhibitors are the hot topic in oncology drug development at the moment, as underscored by numerous speakers during the TAT conference in Paris a few weeks ago. These type of immune-oncology drugs work by the concept of 'i...Read more

SMS-oncology is proud supporter of TAT 2015 congress

SMS-oncology is proud supporter of TAT 2015 congress

27 January 2015, Lindy Bosch, Business Developer

Targeted anticancer therapies - designed to inhibit the unregulated cell growth of cancer cells by targeting specific proteins or pathways or by activating the immune system - serve as the foundation for drug discovery and development no...Read more

EMA anticancer drug approval in 2014

EMA anticancer drug approval in 2014

22 January 2015, Raymond Hoffmans, Chief Business Development Officer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved 82 new drugs in 2014. About 10% of these are used to treat cancer (8 drugs). This is less then in 2013 when 19% of the approved new...Read more

2014

Centralizing personalized medicine in the Netherlands

Centralizing personalized medicine in the Netherlands

15 October 2014, Lindy Bosch

Using the Next Generation Sequencing (NGS) it is currently possible to quickly sequence the whole human genome. It is even within the near future that the technology will permit us to have our personal genome sequenced for a reasonable p...Read more

From Intern to Business Developer: a personal view of working at SMS-oncology

From Intern to Business Developer: a personal view of working at SMS-oncology

25 June 2014, Lindy Bosch

In the current economy, finding a job after graduation is not always easy. I realized that in order for me to get a job that I both like and is in line with my master Biomedical Sciences; Science, Business and Policy, my graduate interns...Read more

Where to publish your oncology Phase I study?

6 March 2014, Raymond Hoffmans

It is important to publish the results of oncology Phase I studies, not only for the investigators who performed the work - as their academic success is often measured by the number of papers they publish - but also for the parties involved.Read more

EMA anticancer drug approvals in 2013

22 January 2014, Raymond Hoffmans

At SMS-oncology, we had a look at the anticancer drugs that were approved by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in 2013. The CHMP approved a total 63 new drugs last year of which 12 are used to treat cancer.Read more

2013

News from the Oncology Arena

7 October 2013, Eric van der Putten

At the ECCO 2013 meeting in Amsterdam promising results were presented from a study with an anti-PD-L1 monoclonal antibody in non-small cell lung cancer. This demonstrated the increasing role of immune blockade in the treatment of cancer in a large and challenging cancer indic...Read more

How adaptive are we?

5 June 2013, Wouter Wijker

Although on some Mondays one is succumbed by the feeling that not a lot is changing in the area of statistics in the pharmaceutical industry, the last ten years has seen a lot of progress in adaptive designs. What is an adaptive clinical trial?Read more

The SMS-oncology 3D Biotech Guideline: Drug Data Dossier

26 March 2013, Edwin Klumper

Biotech Investigator Sponsored Oncology Studies? A double-edged-sword! Investigator Sponsored Studies (ISS) are an attractive mean for start-up biotechs to power their clinical development with their new cancer drug: a cheap way with access to academic expertise and patient data.Read more

SMS-oncology is a proud sponsor of the TAT 2013 Congress

22 January 2013, Eric van der Putten

Targeted therapies, which include monoclonal antibodies and small molecule inhibitors, have significantly changed the treatment of cancer over the past decade. These drugs are now a component of therapy for many common malignancies. A current overview of targeted drug developm...Read more

2012

The CRA - a key element in obtaining clinical proof

4 December 2012, Philine van den Tol

As a Director of Clinical Operations in a specialized early phase oncology CRO, I would like to rethink the role and the necessary skills and attitude of CRAs. It starts with the observation that SMS-oncology attracts the attention of many experienced CRAs wanting to join us.Read more

Let's get personal

30 October 2012, Eric van der Putten

The promise that personalized cancer treatment holds is that patients can be treated as individuals, not merely as members of a "population". Current believe is that future cancer treatments will be truly based on the actual biology of the disease.Read more

The importance of a handshake

17 September 2012, Erik Leferink

New technologies, social media, and "cloud-like" environments have made 'meeting' new people instantaneous and lowered the barrier of distance and geography. Our messages can be quickly spread via LinkedIn, blog posts, collecting "likes" and "retweets". It seems, as a society,...Read more

The future is to the data

20 August 2012, Wouter Wijker

In the past the pharmaceutical companies have always been anti-cyclic businesses and were not affected by the "wows" of the global or local markets. This has changed since 2008 with the start of the financial crisis. Although some say that sufficient money is still available f...Read more

HER2 therapy field on the move

2 July 2012, Raymond Hoffmans

Roche/Genentech's blockbuster antibody Trastuzumab (Herceptin) received FDA approval in 1998 to treat patients with HER2-positive metastatic breast cancer. Subsequently, additional approvals were obtained for HER2-positive early breast cancer and HER2-positive metastatic gastr...Read more

SMS-oncology receives ISO certification

24 May 2012, Eric van der Putten

Last month's introduction of the new SMS-oncology website is just another sign of the continuing growth of our organization. Our service capabilities have broadened consistently over the past two years and the quality of our work meets a higher standard.Read more

SMS-oncology launches new Company Website

26 April 2012, Cyrus Park

In our continuing pursuit to fulfill our mission to become the premier early phase oncology contract research organization, SMS-oncology has revamped and launched a new website to keep our current and future sponsors and collaborators informed of our company's progress and exp...Read more

Contact us for more information Request for proposal